oncology
10 stories tagged "oncology"
The Same Cancer Mutation, Opposite Effects: What 581 Mouse Tumors Say About Who Gets Sick
Cambridge and Yale gave four strains of mice one identical dose of a carcinogen. The tumors converged on the same pathway but took four different genetic routes to get there, and today's screening ignores the reason.
CancerThe Evolutionary Fix for Drug Resistance Works Best on a Tumor Too Small to Find
City St George's mathematicians say hitting a tumor at its weakest moment can drive it extinct. Their own model clears 95 percent only below 7 million cells, far smaller than any tumor a scan can find.
CancerA Cancer Algorithm Found Answers in 71 Children. The 'Quantum' Label Is the Least Interesting Thing About It.
A University of Utah team used the linear algebra of quantum mechanics to pull two survival predictors from just 71 neuroblastoma patients. The science is real. The word doing the marketing is not.
CancerA Repair Gene Turns Saboteur, and a $4 Billion Drug Class Sees an Opening
A Penn State lab found that too much of the DNA repair gene EXO1 makes ordinary tumors behave like BRCA-mutant ones in a dish, and respond to the same drugs. The science is clean. The market context is not.
CancerIvermectin and Cancer: The Review the Horse-Paste Crowd Wasn't Supposed to Get
A 2025 systematic review finds coherent anticancer biology in ivermectin across ten tumor types. The human evidence to match it does not exist. The question of why is what the punchline was designed to bury.
CancerThe "Secret Reason" Cancer Drugs Stop Working Was Published in February
A Montreal team's antibody against the SLAMF6 brake on T cells made the rounds this week as a fresh discovery. The paper went up in February, the work is in mice, and the antibody has not been given to a person.
CancerALTAIR Missed Its Primary Endpoint. The Press Tour Found Something Else.
A phase 3 trial testing chemotherapy in ctDNA-positive colorectal cancer patients missed its primary endpoint at p=0.107, and a post-hoc reanalysis is doing the public-facing work.
CancerSix melanoma patients, six weeks, one common variable: the question oncology is choosing not to study
An oncologist's bedside pattern, a Senate hearing, and a mechanism paper sitting in a mainstream oncology journal: the case that repeated mRNA boosters may be lifting the brakes off cancers oncologists thought they had quiet is no longer fringe enough to wave away.
Drugs & FDAThe Macaques Get a Reprieve. Pharma Gets a Faster Pipeline.
The FDA's new draft guidance lets oncology developers cut animal studies for certain biologics and conjugated products. The replacement laboratory methods are still being validated.
CancerPancreatic cancer's undruggable wall just cracked. The follow-up is 8.5 months and the money was already placed.
Revolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.